This content is for healthcare professionals only.
Please confirm you are a healthcare professional.
Advances in the understanding of the CLL genome has led to the use of genomic and molecular biomarkers such as TP53 genetic alterations and immunoglobulin heavy variable (IgHV) gene mutation status.
Below we hear from leading experts in CLL on the importance of genomic testing, and the impact of these results on diagnosis, prognosis and guiding treatment decisions.
Kostas Stamatopoulos, MD, PhD, Center for Research and Technology Hellas, Thessaloniki, Greece, explains that patients with TP53 aberration and unmutated IgHV are considered high-risk when chemoimmunotherapy is the only available treatment option, however, with the introduction of novel agents, the definition of high-risk CLL is changing.
Richard Rosenquist, MD, PhD, Karolinska Institute, Stockholm, Sweden, explains the importance of genomic tests used in CLL such as fluorescence in situ hybridization (FISH) analysis, TP53 mutation screening and testing of IgHV mutational status, and how these tests can impact treatment decision making and improve the understanding of patient outcomes.
Richard Rosenquist, MD, PhD, Karolinska Institute, Stockholm, Sweden, discusses some of the key tests performed before treatment administration in patients with CLL and explains that in cases of relapse or disease progression, both FISH and TP53 analysis must be performed again to improve subsequent lines of treatment.
Anthony Mato, MD, MSCE, Memorial Sloan Kettering Cancer Center, New York, NY, explains that while morphology and flow cytometry are used in CLL diagnostics, genomic testing plays a key role in the prognosis of CLL and supports the understanding of driver mutations, cancer biology and mechanisms of resistance, and helps clinicians with the selection of appropriate therapies.
Lukas Frenzel, MD, University of Cologne, Cologne, Germany, discusses the importance of testing for TP53 mutation when making treatment decisions in CLL, the role of TP53 as a master regulator of apoptosis and the role that this gene plays in influencing patient response to different therapies.
Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, discusses the importance of genomic testing for detecting TP53 mutation and other genetic aberrations such as IgHV subtypes, the need to monitor patients with high-risk cytogenetics closely and the need to incorporate genomic testing when considering time-limited or continuous treatment plans for patients.
Received honoraria from AbbVie, AstraZeneca, Illumina, Janssen, and Roche
Research support: TG Therapeutics, Pharmacyclics, Abbvie, Adaptive Biotechnologies, Johnson and Johnson, Acerta / AstraZeneca, DTRM BioPharma, Sunesis, BeiGene, Genentech, Genmab, Janssen, Loxo Oncology, Nurix. Advisory/Consultancy/DSMB: TG Therapeutics, Pharmacyclics, Adaptive Biotechnologies, Abbvie, Johnson and Johnson, Acerta / AstraZeneca, DTRM BioPharma, Sunesis, AstraZeneca, BeiGene, Genentech, Janssen, Loxo Oncology
Abbvie Advisory board
I receive honoraria for presentations and advisory board from several different pharmaceutical companies involved in targeted agents in CLL (Abbvie, BeiGene, BMS, Gilead, Janssen, MSD, Roche).
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest hemonc news and updates
Keep up to date with all the latest news with our monthly newsletter